Sentiment Change Report: Eagle Test Systems Inc (NASDAQ:EGLT)

September 14, 2018 - By Eugene Smith

Egalet Corporation (NASDAQ:EGLT) Logo

Sentiment for Eagle Test Systems Inc (NASDAQ:EGLT)

Eagle Test Systems Inc (NASDAQ:EGLT) institutional sentiment increased to 0.93 in 2018 Q2. Its up 0.23, from 0.7 in 2018Q1. The ratio improved, as 13 funds increased or started new stock positions, while 14 cut down and sold their holdings in Eagle Test Systems Inc. The funds in our partner’s database now own: 7.42 million shares, down from 12.28 million shares in 2018Q1. Also, the number of funds holding Eagle Test Systems Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 9 Increased: 8 New Position: 5.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions. The company has market cap of $19.13 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It currently has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

The stock increased 0.28% or $0.001 during the last trading session, reaching $0.353. About 190,162 shares traded. Egalet Corporation (NASDAQ:EGLT) has declined 74.44% since September 14, 2017 and is downtrending. It has underperformed by 90.06% the S&P500.

Analysts await Egalet Corporation (NASDAQ:EGLT) to report earnings on November, 14. They expect $-0.25 earnings per share, up 45.65 % or $0.21 from last year’s $-0.46 per share. After $-0.17 actual earnings per share reported by Egalet Corporation for the previous quarter, Wall Street now forecasts 47.06 % negative EPS growth.

Highbridge Capital Management Llc holds 0.01% of its portfolio in Egalet Corporation for 1.48 million shares. Nj State Employees Deferred Compensation Plan owns 90,000 shares or 0.01% of their US portfolio. Moreover, Advisory Services Network Llc has 0% invested in the company for 1,835 shares. The Illinois-based Alyeska Investment Group L.P. has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 4,296 shares.

Egalet Corporation (NASDAQ:EGLT) Ratings Coverage

Ratings analysis reveals 50% of Egalet Corp’s analysts are positive. Out of 2 Wall Street analysts rating Egalet Corp, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $1.5 while the high is $1.5000. The stock’s average target of $1.50 is 324.93% above today’s ($0.353) share price. EGLT was included in 2 notes of analysts from May 8, 2018. On Tuesday, May 8 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. JMP Securities maintained the shares of EGLT in report on Thursday, August 9 with “Market Outperform” rating.

Egalet Corporation (NASDAQ:EGLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: